본 보고서에서는 재발 완화형 다발성 경화증(RRMS)을 상세하게 조사하여 다발성 경화증의 유병 사례 총계, 진단 유병 사례 총계, RRMS의 진단 유병 사례 총계, RRMS의 연령별 사례, RRMS의 성별 발생 사례, RRMS의 치료 사례 등의 과거 및 향후 역학 데이터를 제시 또한 진단 프로세스, 처방 패턴, 의사의 견해, 시장 접근, 치료 옵션, 시장 전망 동향을 미국, EU 4개국(독일, 프랑스, 이탈리아, 스페인), 영국, 일본의 주요 7개국 시장에 걸쳐 2020-2034년 기간으로 분석했습니다. 또한 기존의 치료실태와 미충족 수요를 종합적으로 평가하여 시장의 잠재력과 새로운 사업 기회를 명확히 하고 있습니다.
DelveInsight's comprehensive report titled "Relapsing-Remitting Multiple Sclerosis (RRMS) - Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of relapsing-remitting multiple sclerosis. The report presents historical and projected epidemiological data covering Total Prevalent Cases of Multiple Sclerosis, Total Diagnosed Prevalent Cases of Multiple Sclerosis, Total Diagnosed Prevalent Cases of Relapsing-Remitting Multiple Sclerosis (RRMS), Age-specific Cases of Relapsing-Remitting Multiple Sclerosis (RRMS), Gender-specific Cases of Relapsing-Remitting Multiple Sclerosis (RRMS), and Treated Cases of Relapsing-Remitting Multiple Sclerosis (RRMS). In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.
The report analyzes the existing treatment practices and unmet medical requirements in Relapsing-Remitting Multiple Sclerosis (RRMS). It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.
Relapsing-Remitting Multiple Sclerosis (RRMS) Overview
Relapsing-remitting multiple sclerosis (RRMS) is the most common form of multiple sclerosis. It is characterized by clearly defined relapses, periods of new or worsening neurological symptoms followed by periods of partial or complete recovery (remissions). The cause of relapsing-remitting multiple sclerosis is not fully understood but is believed to involve an autoimmune attack on the central nervous system, leading to inflammation and damage to the myelin sheath that protects nerve fibers. Relapsing-remitting multiple sclerosis often begins in early adulthood and affects more women than men.
Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosis and Treatment Algorithm
The diagnosis of relapsing-remitting multiple sclerosis is primarily clinical, supported by magnetic resonance imaging (MRI) and other tests. Key diagnostic criteria include evidence of lesions in the brain or spinal cord that are separated in both time and space, meaning they occurred at different points and in different locations. MRI scans are critical in detecting these lesions. Additional diagnostic tools include lumbar puncture (to detect oligoclonal bands in cerebrospinal fluid), evoked potentials (to assess nerve conduction), and blood tests to rule out other conditions. The 2017 revisions to the McDonald criteria have improved the sensitivity of relapsing-remitting multiple sclerosis diagnosis, enabling earlier and more accurate etc.
Treatment for relapsing-remitting multiple sclerosis focuses on managing relapses, slowing disease progression, and alleviating symptoms. Disease-modifying therapies (DMTs) are central to long-term management and include a wide range of options such as injectables, oral agents, and infusions. Approved DMTs for relapsing-remitting multiple sclerosis include OCREVUS and ZUNOVO (ocrelizumab and hyaluronidase-ocsq, Genentech), PONVORY (ponesimod, Vanda Pharmaceuticals), VUMERITY (diroximel fumarate, Biogen), MAYZENT (siponimod, Novartis), and others. These therapies help reduce relapse frequency, delay disability progression, and minimize new lesion formation. Acute relapses are often managed with corticosteroids, while symptomatic treatments address issues such as fatigue, spasticity, and mobility challenges. Multidisciplinary care, including physical therapy and lifestyle modifications, also plays a key role in comprehensive relapsing-remitting multiple sclerosis management.
The epidemiology section of the relapsing-remitting multiple sclerosis market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.
This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of relapsing-remitting multiple sclerosis. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.
The Relapsing-Remitting Multiple Sclerosis (RRMS) therapeutics market is projected to experience steady growth over the forecast period (2025-2034), fueled by rising global prevalence, increased awareness, advancements in diagnostic technologies, and the development of more targeted and personalized therapies.
Marketed Relapsing-Remitting Multiple Sclerosis (RRMS) Drugs
OCREVUS ZUNOVO (ocrelizumab and hyaluronidase-ocsq): Hoffmann-La Roche (Genentech)
OCREVUS ZUNOVO is a subcutaneous (SC) formulation of ocrelizumab for multiple sclerosis, enhanced by ENHANZE technology using hyaluronidase (rHuPH20) to increase tissue permeability and speed absorption. It targets CD20-positive B cells, which drive myelin and nerve damage, while sparing vital immune cells. Administered as a 920 mg injection every six months over 10 minutes, it offers a more convenient alternative to IV infusion. Patients require monitoring, one hour after the initial dose and 15 minutes for later doses to ensure safety.
In September 2024, the US FDA approved OCREVUS ZUNOVO as the first and only subcutaneous (SC) treatment for both relapsing and progressive forms of Multiple Sclerosis, including Relapsing-Remitting Multiple Sclerosis (RRMS).
PONVORY (ponesimod): Vanda Pharmaceuticals/Janssen Pharmaceutical
PONVORY (ponesimod), developed by Vanda Pharmaceuticals, is an oral, once-daily sphingosine-1-phosphate (S1P) receptor modulator. It works by preventing immune cells from reaching the central nervous system, thereby reducing inflammation and disease activity. PONVORY offers a convenient oral treatment option with demonstrated efficacy in lowering relapse rates and slowing the progression of multiple sclerosis.
In December 2023, Vanda Pharmaceuticals acquired the US and Canadian rights to PONVORY from Actelion Pharmaceuticals, a Johnson & Johnson company. Approved in 2021 by the FDA for relapsing forms of multiple sclerosis including relapsing-remitting multiple sclerosis.
Emerging Relapsing-Remitting Multiple Sclerosis (RRMS) Drugs
Vidofludimus calcium (IMU-838): Immunic AG
Vidofludimus calcium is an orally administered investigational small molecule drug being developed for chronic inflammatory and autoimmune diseases, currently in late-stage clinical trials for multiple sclerosis. Uniquely, vidofludimus calcium's first-in-class, dual mode of action combines neuroprotective, anti-inflammatory and anti-viral effects to target the complex pathophysiology of multiple sclerosis. As a selective immune modulator, it activates the neuroprotective transcription factor, nuclear receptor-related 1 (Nurr1), which provides direct and indirect neuroprotective effects. Additionally, vidofludimus calcium achieves anti-inflammatory and anti-viral effects through highly selective inhibition of the enzyme dihydroorotate dehydrogenase (DHODH).
In June 2025, Immunic, announced the completion of enrollment for both Phase III ENSURE trials evaluating vidofludimus calcium in patients with relapsing multiple sclerosis, including RRMS. Top-line results from these pivotal studies are expected by the end of 2026.
CLS12311: Cellerys AG
CLS12311 is an investigational cell therapy developed by Cellerys AG, designed to induce antigen-specific immune tolerance in relapsing-remitting multiple sclerosis. It uses a patient's own red blood cells chemically coupled with 5 multiple sclerosis-related peptides to retrain the immune system and reduce autoreactivity.
In June 2024, Cellerys AG announced the initiation of its RED4MS Phase Ib/IIa clinical trial in patients with relapsing-remitting multiple sclerosis, with patient screening now underway. The trial, conducted across four European countries, aims to evaluate the potential of immune tolerance-based therapy as a novel approach for treating relapsing-remitting multiple sclerosis.
Relapsing-Remitting Multiple Sclerosis (RRMS) Market Segmentation
DelveInsight's 'Relapsing-Remitting Multiple Sclerosis (RRMS) - Market Insights, Epidemiology, and Market Forecast - 2034' report provides a detailed outlook of the current and future relapsing-remitting multiple sclerosis market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.
Relapsing-Remitting Multiple Sclerosis (RRMS) Market Size by Countries
The Relapsing-Remitting Multiple Sclerosis (RRMS) market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) relapsing-remitting multiple sclerosis market. This dominance is projected to persist, especially with the potential introduction of new products.
Relapsing-Remitting Multiple Sclerosis (RRMS) Market Size by Therapies
Relapsing-Remitting Multiple Sclerosis (RRMS) Market Size by Therapies is categorized into current and emerging markets for the study period 2020-2034.
This section focuses on the sales uptake of potential relapsing-remitting multiple sclerosis drugs that have recently been launched or are anticipated to be launched in the relapsing-remitting multiple sclerosis market between 2020 and 2034. It estimates the market penetration of relapsing-remitting multiple sclerosis drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the relapsing-remitting multiple sclerosis market.
The emerging relapsing-remitting multiple sclerosis therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the relapsing-remitting multiple sclerosis market.
Relapsing-Remitting Multiple Sclerosis (RRMS) Market Access and Reimbursement
DelveInsight's 'Relapsing-Remitting Multiple Sclerosis (RRMS) - Market Insights, Epidemiology, and Market Forecast - 2034' report provides a descriptive overview of the market access and reimbursement scenario of Relapsing-Remitting Multiple Sclerosis (RRMS).
This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.
KOL Views
To keep up with current Relapsing-Remitting Multiple Sclerosis (RRMS) market trends and fill gaps in secondary findings, we interview KOLs and SMEs' working in the relapsing-remitting multiple sclerosis domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or relapsing-remitting multiple sclerosis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the relapsing-remitting multiple sclerosis unmet needs.
DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 25+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as University of California, Yale School of Medicine, Stanford University, University of Girona, ellvitge-Idibell University Hospital, Walton Centre, and University of Tokyo, among others.
Competitive Intelligence Analysis
We conduct a Competitive and Market Intelligence analysis of the Relapsing-Remitting Multiple Sclerosis (RRMS) Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.
Relapsing-Remitting Multiple Sclerosis (RRMS) Pipeline Development Activities
The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for Relapsing-Remitting Multiple Sclerosis (RRMS). It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.
Pipeline Development Activities
The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging Relapsing-Remitting Multiple Sclerosis (RRMS) therapies.
Frequently Asked Questions
The primary treatment goals for Relapsing-Remitting Multiple Sclerosis (RRMS) are to reduce the frequency and severity of relapses, delay disability progression, and minimize new disease activity as seen on MRI. Additional goals include preserving neurological function, improving quality of life, and managing symptoms such as fatigue, mobility issues, and cognitive impairment. Achieving long-term disease stability through individualized therapy and proactive monitoring is also a key objective.
Managing Relapsing-Remitting Multiple Sclerosis (RRMS) presents several challenges, including the heterogeneous nature of the disease, which makes predicting relapses and treatment response difficult. Treatment-related side effects, long-term adherence, and balancing efficacy with safety remain ongoing concerns. Additionally, limited access to advanced therapies in some regions, high treatment costs, and the lack of curative options contribute to the complexity of care. Monitoring disease progression and managing comorbidities also require a multidisciplinary, long-term approach.
The growth of the Relapsing-Remitting Multiple Sclerosis (RRMS) market is driven by rising disease prevalence, advances in novel therapies such as oral agents and immune tolerance approaches, and increasing awareness leading to early diagnosis. Supportive regulatory frameworks, expanding access in emerging markets, and the shift toward personalized medicine further fuel market expansion by improving treatment outcomes and broadening the eligible patient base.
The report will provide comprehensive insights into the current Relapsing-Remitting Multiple Sclerosis (RRMS) market landscape, emerging therapies, competitive dynamics, regulatory requirements, and market access considerations, enabling informed decision-making, strategic planning, and optimization of business strategies to capitalize on market opportunities and drive growth.